Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087. (4th November 2015) - Chen, Robert; Armand, Phillippe; Fanale, Michelle A; Ribrag, Vincent; Zinzani, Pier Luigi; Ricart, Alejandro D; Thompson, Seth; Balakumaran, Arun; Molin, Daniel; Shipp, Margaret A; Moskowitz, Craig H